Prolonged dexmedetomidine infusion as an adjunct in treating sedation-induced withdrawal.
Dexmedetomidine, an alpha(2)-adrenoceptor agonist, is indicated for sedating patients on mechanical ventilation. It has been approved by the Food and Drug Administration for 24-h use. This is a report concerning a patient in whom a continuous infusion of dexmedetomidine was safely used for a week to help in averting frank withdrawal symptoms from an opioid and benzodiazepines.
Multz
Alan S
AS
Long Island Jewish Medical Center, New Hyde Park, New York.
D000151:Acinetobacter Infections / Q000150:complications; D000328:Adult; D000701:Analgesics, Opioid / Q000009:adverse effects; D020927:Dexmedetomidine / Q000008:administration & dosage / Q000627:therapeutic use*; D005283:Fentanyl / Q000009:adverse effects; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D008140:Lorazepam / Q000009:adverse effects; D008297:Male; D011014:Pneumonia / Q000209:etiology / Q000628:therapy; D011595:Psychomotor Agitation / Q000188:drug therapy; D012128:Respiratory Distress Syndrome / Q000150:complications; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy*; D019966:Substance-Related Disorders / Q000150:complications; D015300:Ventilator Weaning; D012122:Ventilators, Mechanical
D000701:Analgesics, Opioid; D006993:Hypnotics and Sedatives; D020927:Dexmedetomidine; D008140:Lorazepam; D005283:Fentanyl